乳头瘤病毒16型E6,P53,RB,PCNA在宫颈癌中的表达状态及相关性

Human papillomavirus type 16 E6 oncogene and expression of P53, RB and PCNA in human cervical carcinoma

应用核酸原位杂交和免疫组织化学技术，检测人子宫颈癌中人乳头瘤病毒（ＨＰＶ）１６型Ｅ６ＯＲＦ与抑癌基因产物Ｐ５３，ＲＢ和增殖细胞核抗原（ＰＣＮＡ）。在４４例宫颈癌石蜡切片中，原位杂交检测出ＨＰＶ１６Ｅ６ＯＲＦ阳性２７例（６１．３６％），其中免疫组化检测出Ｐ５３、ＲＢ、ＰＣＮＡ阳性分别为８例（２９．６３％），１４例（５２．８５％）、２０例（７４．０７％），而在１７例ＨＰＶ１６Ｅ６阴性标本中Ｐ５３、ＲＢ、ＰＣＮＡ阳性分别为７例（４１．１７％），９例（５２．９４％）、１２例（７０．５８％）。而在５例正常宫颈组织中未测出ＨＰＶ１６Ｅ６ＯＲＦ，ＰＣＮＡ只在宫颈组织上皮基底层细胞中表达。统计学分析表明，ＨＰＶ１６Ｅ６与宫颈癌密切相关（Ｐ＜０．０５），ＰＣＮＡ在宫颈癌与正常宫颈组织中有显著性差异（Ｐ＜０．０５）。未能发现宫颈癌组织中ＨＰＶ１６Ｅ６ＯＲＦ与Ｐ５３蛋白相关性（Ｐ＞０．０５）。

The aim of this study was to get some insights into the relationship between human papillomavirus type 16 E6 transforming gene and the expressed products of tumor suppressor gene, the P53、RB and proliferation cell nuclear antigen (PCNA) in human cervical carcinoma. 44 formalin-fixed paraffin embedded cervical carcinoma sections were screened for P53, RB and PCNA by immunohistochemical assay with their monoclonal antibodies, and for the presence of HPV16 E6 ORF by in situ hybridization with HPV16 E6 DNA probe we have successfully labeled. The presence of HPV16 E6 gene was detected in 27 of 44 specimens (61.3%), including 8 of P53 protein positive (29.63%), 14 of RB protein positive (52.85%), and 20 of PCNA positive (74.07%). Of 17 HPV16 E6 negative cases, there were 7 of P53 protein positive (41.17%), 9 of RB protein positive (52.94%), 12 of PCNA positive (70.58%). There were no HPV16 E6 gene in control group. In positive cases PCNA only expressed in base cells. Our date indicated that HPV16 E6 ORF and PCNA had significantly related to cervical carcinoma. We could not find the relationship between HPV16 E6 ORF and P53, RB, PCNA in cervical carcinoma. There were some HPV16 E6-positive cases, obviously with strong P53, RB immunostaining in cytoplasm but not in nuclei, PCNA immunostaining was strong at the edge of the cervical carcinoma cells than in nuclear of them.